Aktienanalyse zu Supernus Pharmaceuticals Inc (SUPN)SUPNSupernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Supernus Pharmaceuticals Inc is currently a hold. The stock is priced at $43.73, significantly below the analyst price target of $67, indicating potential upside. However, the RSI is at a low 22.035, suggesting the stock is oversold, which could lead to a rebound. The recent merger with Indivior could provide long-term benefits, but the company reported a net loss of over $58 million in Q2, which raises concerns about profitability. Additionally, insider selling has surged by 2510.70%, indicating potential lack of confidence from insiders, which is a risk to consider.

8 analysts cover SUPN: 6 rate it Buy, 2 Hold and 0 Sell. The average price target is 61.33.